> Detailanzeige

Rubió-Casadevall, Jordi; Cirauqui Cirauqui, Beatriz; Martinez Trufero, Javier; Plana Serrahima, Maria; García Castaño, Almudena; Carral Maseda, Alberto; Iglesias Docampo, Lara; Pérez Segura, Pedro; Ceballos Lenza, Isaac; Gutiérrez Calderón, Vanesa; Fuster Salvà, José; Pena Álvarez, Carolina; Hernandez, Irene; del Barco Morillo, Edel; Chaves Conde, Manuel; Martínez Galán, Joaquina; Durán Sánchez, Marisa; Quiroga, Vanesa; Ortega, Eugenia; Mesia, Ricard

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
  • Beteiligte: Rubió-Casadevall, Jordi; Cirauqui Cirauqui, Beatriz; Martinez Trufero, Javier; Plana Serrahima, Maria; García Castaño, Almudena; Carral Maseda, Alberto; Iglesias Docampo, Lara; Pérez Segura, Pedro; Ceballos Lenza, Isaac; Gutiérrez Calderón, Vanesa; Fuster Salvà, José; Pena Álvarez, Carolina; Hernandez, Irene; del Barco Morillo, Edel; Chaves Conde, Manuel; Martínez Galán, Joaquina; Durán Sánchez, Marisa; Quiroga, Vanesa; Ortega, Eugenia; Mesia, Ricard
  • Erschienen: Frontiers Media SA, 2023
  • Erschienen in: Frontiers in Oncology
  • Sprache: Nicht zu entscheiden
  • DOI: 10.3389/fonc.2023.1226939
  • ISSN: 2234-943X
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Objectives</jats:title><jats:p>The aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m<jats:sup>2</jats:sup> weekly and cetuximab 400 mg/m<jats:sup>2</jats:sup> loading dose, and then 250 mg/m<jats:sup>2</jats:sup> weekly) as first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) who are medically unfit for cisplatin-based (PT) chemotherapy.</jats:p></jats:sec><jats:sec><jats:title>Materials and methods</jats:title><jats:p>This retrospective, non-interventional study involved 16 centers in Spain. Inclusion criteria were to have started receiving ERBITAX regimen from January 2012 to December 2018; histologically confirmed SCCHN including oral cavity, oropharynx, hypopharynx, and larynx; age ≥18 years; and platinum (PT) chemotherapy ineligibility due to performance status, comorbidities, high accumulated dose of PT, or PT refractoriness.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 531 patients from 16 hospitals in Spain were enrolled. The median age was 66 years, 82.7% were male, and 83.5% were current/former smokers. Patients were ineligible to receive PT due to ECOG 2 (50.3%), comorbidities (32%), PT cumulative dose ≥ 225 mg/m<jats:sup>2</jats:sup> (10.5%), or PT refractoriness (7.2%). Response rate was 37.7%. Median duration of response was 5.6 months (95% CI: 4.4–6.6). With a median follow-up of 8.7 months (95% CI: 7.7–10.2), median PFS and OS were 4.5 months (95% CI: 3.9–5.0) and 8.9 months (95% CI: 7.8–10.3), respectively. Patients treated with immunotherapy after ERBITAX had better OS with a median of 29.8 months compared to 13.8 months for those who received other treatments. The most common grade ≥ 3 toxicities were acne-like rash in 36 patients (6.8%) and oral mucositis in 8 patients (1.5%). Five (0.9%) patients experienced grade ≥ 3 febrile neutropenia.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This study confirms the real-world efficacy and tolerability of ERBITAX as first-line treatment in recurrent/metastatic SCCHN when PT is not feasible. Immunotherapy after treatment with ERBITAX showed remarkable promising survival, despite potential selection bias.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang